Allarity Therapeutics Financials - Benzinga

Allarity Therapeutics Inc

ALLRNASDAQ

Trade with Public

Trade with Public

$1.41

0.032.17%

At close: Aug 28, 5:00 PM EST

$1.40

-0.01-0.71%

After Hours: 7:16 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Allarity Therapeutics Financials

Allarity Therapeutics (ALLR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Allarity Therapeutics Q2 EPS $(0.21) Beats $(0.25) Estimate

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.25) by 16 percent. This is a 40 percent decrease over losses of $(0.15) per share from

Benzinga Newsdesk

PRO
Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share

Benzinga Newsdesk

PRO
Allarity Therapeutics Q4 EPS $(0.21), Inline, Sales $320.000K

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 87.79 percent increase over losses of $(1.72) per share from the same period last

Benzinga Newsdesk

PRO
Allarity Therapeutics Q3 EPS $(0.19) Beats $(0.21) Estimate

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 97.54 percent increase over losses of $(7.71) per share

Benzinga Newsdesk

Crude Oil Down 2%; US Durable Goods Orders Decline In July

Avi Kapoor

US Stocks Mixed; American Woodmark Posts Downbeat Sales

Avi Kapoor